ArticleWorld journal of urology2026
TROP2 expression is associated with early stage and favorable prognosis in upper tract urothelial carcinoma.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset.International journal of urology : official journal of the Japanese Urological Association · 2026Observational
- TROP2 Expression in Bladder Transurethral Resection Specimens: Correlation With Histological Grade and Survival.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTROP2 has recently emerged as a promising therapeutic target, with the antibody‒drug conjugate sacituzumab govitecan. Nevertheless, its biological and clinical relevance in urothelial carcinoma (UC) has not been fully investigated.
methodsWe evaluated TROP2 protein expression in 114 upper tract UC (UTUC) tissue samples using immunohistochemistry. RNA-seq-based in silico analyses was further performed.
resultsTROP2 expression was predominantly restricted to tumor tissues and was observed in 72 of 114 cases (63%). TROP2 overexpression was associated with papillary morphology, low tumor grade, early pathological T stage, and favorable clinical outcome. Notably, high TROP2 expression was identified as an independent prognostic factor. Additionally, TROP2 expression showed positive correlations with both UPK3 and Nectin-4 expression. In silico analyses further supported these findings, showing that TACSTD2 (the gene encoding TROP2) expression was significantly elevated in tumors of lower stage, low grade, papillary morphology, luminal subtype, and FGFR3-mutated cases, and was correlated with improved prognosis when the Hiroshima cohort-derived cutoff was applied. Furthermore, a significant correlation between TACSTD2 and NECTIN4 gene expression was observed. Bioinformatics analysis using RNA-Seq datasets revealed that the TACSTD2 high group was significantly enriched in gene sets related to tumor metabolic reprogramming, whereas TACSTD2-low tumors showed signatures related to extracellular matrix remodeling and epithelial-mesenchymal transition (EMT).
conclusionsOur findings underscore the clinical significance of TROP2 expression in UTUC and suggest that IHC-based evaluation may contribute to prognostic risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.